| Estee E Fleischman, MD | |
|
10 Gove St, East Boston, MA 02128-1920 | |
| (617) 569-5800 | |
| (617) 568-4780 |
| Full Name | Estee E Fleischman |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 10 Gove St, East Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609288265 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 269977 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna And Hospice Of Greater Milford | Milford, MA | Home health agency |
| Beth Israel Deaconess Hospital - Needham | Needham, MA | Hospital |
| Milford Regional Medical Center | Milford, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Care Of Boston Management Corporation | 6800787714 | 234 |
News Archive
The most common type of hospital-associated infection may be preventable with a vaccine, new research in mice suggests.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
A diagnosis of the brain cancer glioblastoma carries a dismal prognosis, with most patients dying within five years.
Although studies of alcohol's effects on fetal growth have consistently demonstrated deficits that persist through infancy, the data on long-term postnatal growth from human studies have been inconsistent. A new study of the effects of heavy prenatal alcohol exposure (PAE) on growth and body composition throughout childhood has found growth restrictions that persist through to nine years of age, as well as a delay in weight gain during infancy, both of which were exacerbated by iron deficiency.
› Verified 1 days ago
| Entity Name | Medical Care Of Boston Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437196359 PECOS PAC ID: 6800787714 Enrollment ID: O20040322000778 |
News Archive
The most common type of hospital-associated infection may be preventable with a vaccine, new research in mice suggests.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
A diagnosis of the brain cancer glioblastoma carries a dismal prognosis, with most patients dying within five years.
Although studies of alcohol's effects on fetal growth have consistently demonstrated deficits that persist through infancy, the data on long-term postnatal growth from human studies have been inconsistent. A new study of the effects of heavy prenatal alcohol exposure (PAE) on growth and body composition throughout childhood has found growth restrictions that persist through to nine years of age, as well as a delay in weight gain during infancy, both of which were exacerbated by iron deficiency.
› Verified 1 days ago
| Entity Name | Internal Medical Associates-ebnhc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558481879 PECOS PAC ID: 6103814371 Enrollment ID: O20040505000853 |
News Archive
The most common type of hospital-associated infection may be preventable with a vaccine, new research in mice suggests.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
A diagnosis of the brain cancer glioblastoma carries a dismal prognosis, with most patients dying within five years.
Although studies of alcohol's effects on fetal growth have consistently demonstrated deficits that persist through infancy, the data on long-term postnatal growth from human studies have been inconsistent. A new study of the effects of heavy prenatal alcohol exposure (PAE) on growth and body composition throughout childhood has found growth restrictions that persist through to nine years of age, as well as a delay in weight gain during infancy, both of which were exacerbated by iron deficiency.
› Verified 1 days ago
| Entity Name | East Boston Neighborhood Health Center Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316994411 PECOS PAC ID: 9032356050 Enrollment ID: O20130513000045 |
News Archive
The most common type of hospital-associated infection may be preventable with a vaccine, new research in mice suggests.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
A diagnosis of the brain cancer glioblastoma carries a dismal prognosis, with most patients dying within five years.
Although studies of alcohol's effects on fetal growth have consistently demonstrated deficits that persist through infancy, the data on long-term postnatal growth from human studies have been inconsistent. A new study of the effects of heavy prenatal alcohol exposure (PAE) on growth and body composition throughout childhood has found growth restrictions that persist through to nine years of age, as well as a delay in weight gain during infancy, both of which were exacerbated by iron deficiency.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Estee E Fleischman, MD 10 Gove St, East Boston, MA 02128-1920 Ph: (617) 569-5800 | Estee E Fleischman, MD 10 Gove St, East Boston, MA 02128-1920 Ph: (617) 569-5800 |
News Archive
The most common type of hospital-associated infection may be preventable with a vaccine, new research in mice suggests.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
A diagnosis of the brain cancer glioblastoma carries a dismal prognosis, with most patients dying within five years.
Although studies of alcohol's effects on fetal growth have consistently demonstrated deficits that persist through infancy, the data on long-term postnatal growth from human studies have been inconsistent. A new study of the effects of heavy prenatal alcohol exposure (PAE) on growth and body composition throughout childhood has found growth restrictions that persist through to nine years of age, as well as a delay in weight gain during infancy, both of which were exacerbated by iron deficiency.
› Verified 1 days ago
Anu Rupa Mehra, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4780 | |
Shereen Mohiuddin, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4780 | |
Karin Leschly, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4780 | |
Charles T Williams, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4780 | |
Jennifer L Pfau, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4780 | |
Dr. Jackie S Fantes, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4780 | |
John Paul O'brien, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Gove St, East Boston, MA 02128 Phone: 617-569-5800 Fax: 617-568-4756 |